Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Ezetimibe (Zetia) vs Inclisiran (Leqvio): Ezetimibe (Zetia) has the stronger overall evidence (4.4 vs 4.1/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Ezetimibe (Zetia) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (3)
Outcomes where both Ezetimibe (Zetia) and Inclisiran (Leqvio) have evidence — compare verdict strength side-by-side.
10 mg once daily, with or without food, alone or added to a statin — under a clinician. A prescription drug; not a self-directed supplement regimen.
Any time of day
Oral tablet (ezetimibe 10 mg)
284 mg (300 mg inclisiran sodium) by subcutaneous injection administered by a healthcare professional on day 1, again at day 90 (month 3), then every 6 months thereafter. A prescription drug; this is the approved regimen, not a self-directed supplement protocol.
Any time of day
Prefilled subcutaneous injection (inclisiran 284 mg)
and 1 more not shown
2–4 weeks
Months to years
Throughout use
Throughout use
Weeks to months; sustained
Ongoing
Outcomes trials ongoing
Around each injection
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
The New England journal of medicine (2015) · Rct · n=18144
IMPROVE-IT randomized trial: ~18,000 patients stabilized after acute coronary syndromes
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Lancet (London, England) (2011) · Rct · n=9438
SHARP randomized placebo-controlled trial in chronic kidney disease (n≈9,400)
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
The New England journal of medicine (2008) · Rct · n=1873
SEAS randomized trial in patients with mild-to-moderate aortic stenosis
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
The New England journal of medicine (2020) · Rct · n=3178
ORION-10 and ORION-11 randomized, placebo-controlled phase 3 trials in atherosclerotic cardiovascular disease / high risk
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
The New England journal of medicine (2020) · Rct · n=482
ORION-9 randomized, placebo-controlled phase 3 trial in heterozygous familial hypercholesterolemia
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
The New England journal of medicine (2017) · Rct · n=501
ORION-1 phase 2, double-blind, placebo-controlled, multiple-ascending-dose trial
Ezetimibe (Zetia) has a higher evidence score (4.4/10 vs 4.1/10) and wins in 2 of 3 categories.
For support heart health, Inclisiran (Leqvio) has a higher relevance score (70 vs 68).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.